How ctDNA Is Reshaping Precision Oncology

Precision oncology is reshaping how oncology trials are designed and delivered.

From Glucose Control to Disease Strategy: What ADA 2026 Revealed About the Future of Diabetes Development

Navigating the Regulatory Path for ctDNA in Precision Oncology

As circulating tumor DNA (ctDNA) becomes more embedded in oncology research and clinical decision-making, regulatory considerations are increasingly central.

How is FDA single pivotal trial guidance reshaping End of Phase 2 strategy?

Radiopharmaceutical Trials: An Operational Playbook

Leveraging Sentiment Analysis to Evaluate Clinical Outcome Assessments

Spain Public Country-by-Country Report

Rethinking Clinical Outcome Assessments: What Sentiment Analysis Reveals About Patient Feedback